Assessment of the efficacy and safety of favipiravir in patients with SARS-CoV-2 infection in United Arab Emirates: A single-center study

Main Article Content

Bayan Ayash https://orcid.org/0000-0001-6382-7046
Sahab Alkhoujah https://orcid.org/0000-0001-9718-419X
Neena Abraham https://orcid.org/0000-0002-8532-6354
Ahmad El Ouweini https://orcid.org/0000-0002-7109-6340
Sara Mansour https://orcid.org/0000-0002-3351-4636
Syed Wassif Gillani https://orcid.org/0000-0003-4327-2068
Rabih Hallit https://orcid.org/0000-0003-1817-6146
Souheil Hallit https://orcid.org/0000-0001-6918-5689
Diana Malaeb https://orcid.org/0000-0002-2436-850X

Keywords

COVID-19, favipiravir, symptomatic management, safety, efficacy

Abstract

Background: Anti-viral medications are among the treatment options for coronavirus infectious disease 2019 (COVID-19) management although they are still not FDA approved for coronavirus treatment. We conducted the study to assess the efficacy, and safety of favipiravir versus symptomatic management in patients with COVID-19. Methods: A cross-sectional study included 476 participants, divided into two groups. All patients received symptomatic management, and 300 received favipiravir 1,600 mg/day on day 1 and 600 mg/day on days 2 to 5. Results: The mean age of the patients was 44.18 ± 12.24 years (49.2% females). The most described COVID-19 symptoms was cough, followed by sore throat, headache, and fever. Each side effect of favipiravir was experienced by almost 38% of the patients. The average days for symptoms relief was 4.73 ± 2.25 days. The results of the linear regression showed that the intake of favipiravir vs symptomatic management only was significantly associated with a higher mean number of days until symptoms relief. Conclusion: The results highlight that efficacy of favipiravir is not supported yet for the treatment of COVID-19 as it was associated with higher mean number of days until symptoms relief. However, no remarkable issues with safety associated with Favipiravir were observed.

Abstract 61 | PDF Downloads 38

References

1. World Health Organization. WHO Director-General’s opening remarks at the mission briefing on COVID-19. 2020 [Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-mediabriefing- on-covid-19---11-march-2020].
2. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19. N Engl J Med. 2020;382(22):2158-60. https://doi.org/10.1056/nejme2009758
3. Dabbous HM, Abd-Elsalam S, El-Sayed MH, et al. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol. 2021;166(3):949-54. https://doi.org/10.1007/s00705-021-04956-9
4. Pal JK. Visualizing the knowledge outburst in global research on COVID-19. Scientometrics. 2021;126(5):4173-93. https://doi. org/10.1007/s11192-021-03912-3
5. Chandiwana N, Kruger C, Johnstone H, et al. Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial. EBioMedicine. 2022;86:104322. https://doi.org/10.1016/j.ebiom.2022.104322
6. Yanagisawa K, Takara K, Suga H, et al. The Assessment of the Efficacy and Safety of Favipiravir for Patients with SARS-CoV-2 Infection: A Multicenter Non-randomized, Uncontrolled Single-arm Prospective Study. Intern Med. 2022;61(21):3197-204. https://doi.org/10.2169/internalmedicine.9691-22
7. Arshad U, Pertinez H, Box H, et al. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Clin Pharmacol Ther. 2020;108(4):775-90. https://doi.org/10.1002/cpt.1909
8. Duvignaud A, Lhomme E, Pistone T, et al. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial). Trials. 2020;21(1):846. https://doi.org/10.1186/s13063-020-04619-1
9. Cascella M, Rajnik M, Aleem A, et al. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.; 2022.
10. Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002;46(4):977-81. https://doi.org/10.1128/aac.46.4.977-981.2002
11. Goldhill DH, Te Velthuis AJW, Fletcher RA, et al. The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci U S A. 2018;115(45):11613-8. https://doi.org/10.1073/pnas.1811345115
12. Zhu W, Chen CZ, Gorshkov K, et al. RNA-Dependent RNA Polymerase as a Target for COVID-19Drug Discovery. SLAS Discov. 2020;25(10):1141-51. https://doi.org/10.1177/2472555220942123
13. Alamer A, Alrashed AA, Alfaifi M, et al. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Curr Med Res Opin. 2021;37(7):1085-97. https://doi.org/10.1080/03007995.2021.1920900
14. Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62-71. https://doi.org/10.1016/j.ijid.2020.11.142
15. Hassanipour S, Arab-Zozani M, Amani B, et al. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021;11(1):11022. https://doi.org/10.1038/s41598-021-90551-6
16. Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020;6(10):1192-8. https://doi.org/10.1016/j.eng.2020.03.007
17. Chen C, Zhang Y, Huang J, et al. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Front Pharmacol. 2021;12:683296. https://doi.org/10.3389/fphar.2021.683296
18. Yamakawa K, Yamamoto R, Ishimaru G, et al. Japanese rapid/living recommendations on drug management for COVID-19. Acute Med Surg. 2021;8(1):e664. https://doi.org/10.1002/ams2.664
19. Alshahrani NZ, Algethami MR, Alarifi AM, et al. Knowledge and Attitude Regarding Monkeypox Virus among Physicians in Saudi Arabia: A Cross-Sectional Study. Vaccines (Basel). 2022;10(12). https://doi.org/10.3390/vaccines10122099
20. Yasui Y, Yasui H, Suzuki K, et al. Analysis of the predictive factors for a critical illness of COVID-19 during treatment - relationship between serum zinc level and critical illness of COVID-19. Int J Infect Dis. 2020;100:230-6. https://doi.org/10.1016/j. ijid.2020.09.008
21. World Health Organization. A healthy lifestyle - WHO recommendations [Internet]. Available from: https://www.who.int/ europe/news-room/fact-sheets/item/a-healthy-lifestyle---who-recommendations [ 22. Circular No (2022/186) – Updates on COVD-19 Cases and Contact Management Procedures.
23. DOH. National Guidelines for Clinical Management and Treatment of COVID-19 18 th February 2021.
24. Hase R, Kurata R, Ishida K, et al. Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019. Internal Medicine. 2020;59:2327 - 9. https://doi.org/10.2169/internalmedicine.5377-20
25. Kocayiğit H, Özmen Süner K, Tomak Y, et al. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19. J Clin Pharm Ther. 2021;46(2):454-9. https://doi.org/10.1111/jcpt.13305
26. World Health Organization. Clinical management of COVID-19 - Living guideline [Internet]. Available from: https://reliefweb. int/report/world/clinical-management-covid-19-living-guidance-25-january-2021?gclid=CjwKCAiAuOieBhAIEiwAgjCvciAVSsQ LGdSsE44pJ065JVHYEVbYn9gXQX9VJUjAw8RuZK1oKpKi8BoCC_QQAvD_BwE.
27. ABU DHABI PUBLIC HEALTH CENTRE. Department of health. Circulars. Important documents for professionals. [Internet]. Available from: https://www.doh.gov.ae/en/covid-19/Healthcare-Professionals/Circulars.
28. Hung DT, Ghula S, Aziz JMA, et al. The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies. Int J Infect Dis. 2022;120:217-27. https://doi. org/10.1016/j.ijid.2022.04.035
29. Sustersic M, Gauchet A, Kernou A, et al. A scale assessing doctor-patient communication in a context of acute conditions based on a systematic review. PLoS One. 2018;13(2):e0192306. https://doi.org/10.1371/journal.pone.0192306
30. Ibrahim L, Ibrahim L, Hallit S, et al. Validation of the Lebanese Medication Adherence Scale among Lebanese diabetic patients. Int J Clin Pharm. 2021;43(4):918-27. https://doi.org/10.1007/s11096-020-01197-9
31. Hair JF Jr, Hult GTM, Ringle C, et al. A primer on partial least squares structural equation modeling (PLS-SEM): Sage publications 2017.
32. Shinkai M, Tsushima K, Tanaka S, et al. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. Infect Dis Ther. 2021;10(4):2489-509. https://doi.org/10.1007/s40121- 021-00517-4
33. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693- 704. https://doi.org/10.1056/nejmoa2021436
34. Shrestha DB, Budhathoki P, Khadka S, et al. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J. 2020;17(1):141. https://doi.org/10.1186/s12985-020-01412-z
35. Pérez-García A, Villalobos-Osnaya A, Hernández-Medel ML, et al. A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults. “COMVIVIR” Trial. Research Square; 2020.
36. Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497-511. https://doi.org/10.1056/nejmoa2023184
37. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787-99. https://doi.org/10.1056/nejmoa2001282
38. Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022;22(2):209-21. https://doi.org/10.1016/s1473-3099(21)00485-0
39. Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022;386(4):305-15. https://pubmed.ncbi.nlm.nih.gov/34937145/
40. Khamis F, Al Naabi H, Al Lawati A, et al. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis. 2021;102:538-43. https://doi.org/10.1016/j.ijid.2020.11.008
41. Erdem HA, Korkma PE, Çağlayan D, et al. Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey. Turk J Med Sci. 2021;51(3):912-20. https://doi.org/10.3906/sag-2008-33

Most read articles by the same author(s)

1 2 3 > >>